Kiora's KIO-300 suppresses seizure activity in preclinical epilepsy model
Kiora Pharmaceuticals announced preclinical data showing KIO-300 significantly reduced seizure-associated activity in a temporal lobe epilepsy model, suggesting therapeutic potential beyond its current ophthalmology focus. The findings could expand the company's ion channel modul
View filing at SEC.gov →